查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2000853

新型药物递送系统市场：按产品类型、给药途径、技术、应用和最终用户划分－2026-2032年全球市场预测

Novel Drug Delivery Systems Market by Product Type, Route Of Administration, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，新型药物输送系统市场价值将达到 164 亿美元，到 2026 年将成长至 179.5 亿美元，到 2032 年将达到 311.3 亿美元，复合年增长率为 9.57%。

主要市场统计数据
基准年 2025 164亿美元
预计年份：2026年 179.5亿美元
预测年份：2032年 311.3亿美元
复合年增长率 (%) 9.57%

全面概述跨学科创新和以患者为中心的设计如何重新定义新型药物输送平台的目的和潜力。

随着分子水平创新与先进材料科学和以患者为中心的护理模式相融合，药物递送领域正在经历根本性的变革。新型药物递送系统涵盖了从吸入装置和注射剂到经皮吸收贴片以及最先进的微奈米载体等多种平台，每一种都旨在提高治疗指数、患者依从性和靶向生物分布。本执行摘要介绍了影响生物製药、医疗技术和专业医疗设备公司发展重点和投资策略的关键技术、监管和商业性转折点。

精准标靶、数位整合和策略伙伴关係如何重塑创造临床价值和实现先进药物递送商业化的途径？

多项变革正在加速药物递送技术的演进，并重新定义新治疗方法的成功标准。首先，奈米颗粒、脂质奈米颗粒系统和植入式装置实现的精准标靶递送已从概念验证发展到实际临床应用阶段，从而能够在病灶部位提高治疗药物浓度，同时降低全身暴露。这项技术的成熟与监管机构对复合製剂和新型辅料的日益认可相吻合，使得更具雄心的製剂和整合式装置解决方案成为可能。

2025 年美国关税调整对采购、製造在地化和供应链韧性的营运和策略影响。

2025年美国关税环境对整个生命科学供应链造成了微妙的营运和战略压力，从多方面影响零件采购、製造地选择和成本结构。针对特定原料和医疗设备零件的关税措施提高了某些聚合物、特殊脂质和用于连网型设备的电子子系统的进口成本。这种变化促使那些先前依赖全球化成本优化筹资策略的製造商重新评估其营运模式。

基于可操作的细分情报进行精确的策略定位，将给药途径、底层技术、治疗应用、产品类型和最终用户管道连结起来。

细分市场层面的趋势揭示了不同的机会和技术限制，这些都应体现在研发优先事项和商业规划中。就给药途径而言，吸入平台（包括干粉吸入器和雾化器）正在被重新开发，以支持生物製药和局部肺部治疗；而注射製剂（包括肌肉注射、静脉注射和皮下注射）仍然是全身性生物製药和长效缓释製剂的核心。鼻腔给药（透过滴鼻剂和滴鼻剂）是快速实施中枢神经系统 (CNS) 和黏膜免疫策略的一种很有前景的途径；而口服给药（透过胶囊、液体和片剂）在稳定性和患者依从性方面仍在不断优化。经经皮给药（透过凝胶和贴片）在治疗慢性疾病、稳定状态以及需要稳定血浆浓度曲线的疗法中越来越受到关注。

美洲、欧洲、中东、非洲和亚太地区的监管环境、还款状况和製造业趋势将如何影响发展重点和市场进入顺序？

区域趋势决定了新型给药系统的研发、生产和商业化的优先事项。在美洲，生技药品和植入式医疗设备创新丛集与完善的报销机制并存，加速了产品的普及应用。然而，供应链和关税方面的考量使得本地化生产和监管协调至关重要。欧洲、中东和非洲的情况则呈现多样性。在一些欧洲市场，成熟的监管管道和集中采购体係有利于先进医疗设备和复合产品的发展，而该地区的新兴市场则可能优先考虑成本效益高、易于操作的解决方案和分散式医疗模式。亚太地区拥有庞大的患者群体、不断扩展的临床试验能力以及快速扩大产业规模的潜力，因此蕴藏着丰富的机会。但进入亚太市场需要仔细考虑各国具体的监管细则和对在地化生产的期望。

透过整合技术堆迭、策略合作伙伴关係以及对真实世界数据和卓越製造的关注，实现竞争差异化。

新型药物递送系统领域的竞争格局呈现出多元化的特点，既有成熟的製药公司，也有医疗设备专家和敏捷的技术创新者。主要企业凭藉垂直整合的能力脱颖而出，这些能力涵盖製剂科学、器械工程和生产规模化，从而能够快速从概念阶段过渡到临床试验阶段。从许可和共同开发契约到股权投资，各种策略联盟是获取互补能力的常用手段，尤其是在奈米颗粒工程、微针製造和数位健康整合等领域。

生命科学产业的领导者需要采取切实可行、优先排序和具有战略意义的行动，以协调研发、供应链韧性和创造永续应用的商业性证据。

行业领导者应采取一系列优先行动，将技术潜力转化为可持续的商业性成果。首先，他们应在药物研发早期阶段就整合发行策略，与临床和监管团队合作设计製剂和装置，从而最大限度地减少后期重新设计，并加快核准准备工作。其次，他们应实现供应链多元化，并对替代材料和供应商进行认证，以降低关税和地缘政治风险，同时在关键组件的采购中采用冗余机制。第三，对于包括脂质奈米颗粒和奈米颗粒系统在内的复杂製剂，他们应投资于中试生产和可扩展的製程验证，以便在产品进入III期临床试验时缩短大规模生产的时间。

采用可重复的混合方法研究方法，结合严格的第二手资料审查和对专家的直接访谈，来检验技术的成熟度和商业性趋势。

本报告基于结构化的调查方法，结合了多方面的二手资料分析和有针对性的原始研究，从而确保了研究结果的可靠性、实用性和可重复性。二手资料分析包括对同行评审文献、监管指导文件、专利申请和技术白皮书的精选审查，旨在捕捉技术趋势、监管先例和材料科学领域的进展。透过这些二手资料分析所获得的洞见建立了一个基本的分类系统，用于对给药途径、底层技术、治疗应用、产品类型和最终用户管道进行分类。

整合技术、营运和商业性需求，以确定哪些交付技术创新将在临床实践和市场中产生可扩展的影响。

总之，新型药物递送系统正从利基技术示范阶段迈向决定治疗差异化和病患疗效的核心策略资产。先进材料、设备工程和数位健康技术的融合正在拓展标靶递送、缓释和微创给药的可能性。同时，地缘政治和政策的变化，包括关税和区域製造预期的变化，使得供应链的韧性和本地化成为一项战略挑战，影响成本结构和监管管道。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：新型药物输送系统市场：依产品类型划分

  • 缓释注射药物
    • 可生物降解
    • 不可生物降解
  • 涂药支架
    • 冠状动脉
    • 外围
  • 嵌入式泵浦
    • 点滴帮浦
    • 渗透泵浦
  • 脂质奈米颗粒製剂
    • 传统脂质奈米颗粒
    • 隐形脂质奈米颗粒
  • 微针贴片
    • 溶解度
    • 固态的

第九章：新型药物递送系统市场：依给药途径划分

  • 吸入
    • 干粉吸入器
    • 喷雾器
  • 注射
    • 肌肉内部
    • 静脉
    • 皮下
  • 鼻腔
    • 滴鼻剂
    • 喷
  • 口服
    • 胶囊
    • 液体
    • 药片
  • 经皮
    • 凝胶
    • 修补

第十章：新型药物输送系统市场：依技术划分

  • 水凝胶
    • 自然的
    • 合成
  • 植入
    • 可生物降解
    • 不可生物降解
  • 微型针
    • 覆盖类型
    • 溶解度
    • 中空的
    • 固体的
  • 奈米颗粒
    • 树状聚合物
    • 脂质奈米颗粒
      • 阳离子脂质奈米颗粒
      • 隐形脂质奈米颗粒
    • 聚合物奈米粒子
    • 固体脂质奈米颗粒

第十一章：新型药物传输系统市场：依应用领域划分

  • 循环系统
    • 支架
    • 经导管装置
  • 内分泌学
    • 糖尿病管理
    • 荷尔蒙补充疗法
  • 感染疾病
    • 抗生素输送
    • 抗病毒药物递送
    • 疫苗接种
  • 神经病学
    • 中枢神经系统疾病
    • 週边疾病
  • 肿瘤学
    • 化疗
    • 免疫疗法
    • 标靶治疗
  • 眼科
    • 眼药水
    • 眼内植入

第十二章：新型药物输送系统市场：依最终用户划分

  • 门诊治疗
  • 诊所
  • 居家照护
  • 医院
  • 药局

第十三章：新型药物输送系统市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：新型药物递送系统市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：新型药物输送系统市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国新型药物传输系统市场

第十七章：中国新型药物输送系统市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galen Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samyang Holdings Corporation
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-02026C4CB9B9

The Novel Drug Delivery Systems Market was valued at USD 16.40 billion in 2025 and is projected to grow to USD 17.95 billion in 2026, with a CAGR of 9.57%, reaching USD 31.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.40 billion
Estimated Year [2026] USD 17.95 billion
Forecast Year [2032] USD 31.13 billion
CAGR (%) 9.57%

A comprehensive orientation to how multidisciplinary innovation and patient-centric design are redefining the purpose and opportunity of novel drug delivery platforms

The landscape of drug delivery is undergoing a fundamental redefinition as molecular innovation converges with advanced materials science and patient-centric care models. Novel drug delivery systems encompass a broad array of platforms-from inhalation devices and injectable formats to transdermal patches and cutting-edge micro- and nano-scale carriers-each engineered to enhance therapeutic index, adherence, and targeted biodistribution. This executive summary synthesizes the critical technological, regulatory, and commercial inflection points that are shaping development priorities and investment strategies across biopharma, medtech, and specialty device companies.

Across therapeutic areas, developers are prioritizing delivery as an integral component of drug value rather than a peripheral enabler. This shift is driving more integrated product development lifecycles where formulation scientists, device engineers, and clinical teams co-design solutions to meet complex safety, stability, and usability requirements. Moreover, the growing emphasis on outpatient care and at-home administration is reshaping product specifications and supply chain considerations. As a result, stakeholders who can align scientific innovation with real-world usability and reimbursement pathways will have a decisive advantage in commercializability and patient uptake.

How precision targeting, digital integration, and strategic partnerships are remapping clinical value creation and commercialization pathways in advanced delivery

Several transformative shifts are accelerating the evolution of drug delivery and redefining what success looks like for new therapeutic modalities. First, precision targeting-enabled by nanoparticles, liposomal systems, and implantable devices-has advanced from proof-of-concept to practical clinical application, enabling higher therapeutic concentrations at disease sites while reducing systemic exposure. This technical maturation coincides with regulatory receptivity to combination products and novel excipients, which permits more ambitious formulations and integrated device solutions.

Concurrently, digital health integration is changing the expectations for adherence monitoring and dose personalization. Smart implants, connected infusion pumps, and sensor-integrated patches are moving delivery systems from passive carriers to active participants in care pathways. The commercial landscape is also shifting: strategic partnerships between pharmaceutical firms and specialty device companies are more common, reflecting recognition that complementary expertise is required to navigate complex development, manufacturing, and lifecycle management challenges. Taken together, these dynamics are producing a landscape where cross-functional collaboration, regulatory agility, and supply chain resilience determine which innovations scale into meaningful clinical and commercial outcomes.

Operational and strategic consequences of the United States tariff adjustments in 2025 that reshaped sourcing, manufacturing localization, and supply chain resilience

The tariff environment in the United States in 2025 introduced nuanced operational and strategic pressures across the life sciences supply chain, with variable effects on component sourcing, manufacturing location decisions, and cost structures. Tariff measures targeting specific raw materials and device components increased import costs for certain polymers, specialized lipids, and electronic subsystems used in connected devices. This change prompted an operational reassessment among manufacturers who had previously relied on globalized, cost-optimized sourcing strategies.

In response, many organizations accelerated localization of critical supply chains or established dual-sourcing arrangements to mitigate exposure to tariff volatility. Raising procurement and manufacturing visibility became a priority, as did increased investment in supply chain analytics to model tariff sensitivity across product portfolios. Importantly, these adjustments have implications beyond near-term cost management: decisions to regionalize production, qualify alternative materials, or redesign device architectures are influencing regulatory submission strategies and time-to-market calculations. Companies that proactively integrated tariff scenario planning into their commercialization roadmaps were better positioned to preserve margin and continuity of supply while maintaining development timelines.

Actionable segmentation intelligence linking routes of administration, enabling technologies, therapeutic applications, product typologies, and end-user channels for precise strategic targeting

Segment-level dynamics reveal differentiated opportunities and technical constraints that should inform R&D prioritization and commercial planning. When considering route of administration, inhalation platforms-encompassing dry powder inhalers and nebulizers-are being redeveloped to support biologics and localized pulmonary therapies, while injectable formats, including intramuscular, intravenous, and subcutaneous variants, remain central for systemic biologics and long-acting depot approaches. Nasal delivery through drops and sprays offers a compelling route for rapid CNS and mucosal immunization strategies, and oral delivery across capsules, liquids, and tablets continues to be optimized for stability and patient adherence. Transdermal options, realized through gels and patches, are increasingly attractive for chronic, steady-state therapies and for therapies requiring steady plasma profiles.

From a technology perspective, hydrogels-both natural and synthetic-are maturing as sustained-release matrices, whereas implants, whether biodegradable or nonbiodegradable, support long-duration local therapies and reduced dosing frequency. Microneedles in coated, dissolvable, hollow, and solid formats provide minimally invasive delivery with potential for self-administration, and nanoparticle platforms, including dendrimers, various liposome classes, polymeric nanoparticles, and solid lipid nanoparticles, enable targeted delivery and controlled release. Application-driven segmentation illuminates where clinical need and commercialization potential intersect: cardiovascular interventions that leverage stents and transcatheter devices, endocrinology solutions focused on diabetes management and hormone therapies, infectious disease delivery channels for antibiotics, antivirals, and vaccines, neurology approaches for central and peripheral disorders, oncology delivery systems for chemotherapy, immunotherapy, and targeted agents, and ophthalmology solutions spanning eye drops to ocular implants.

Product-type distinctions further refine go-to-market considerations: depot injections, both biodegradable and nonbiodegradable, offer adherence advantages; drug-eluting stents for coronary and peripheral use require procedural integration; implantable pumps such as infusion and osmotic pumps demand durable power and control solutions; liposomal formulations-standard and stealth variants-affect pharmacokinetics and immunogenicity; and microneedle patches, in dissolvable and solid forms, present unique manufacturing scale-up pathways. Finally, end-user segmentation spanning ambulatory care, clinics, home care, hospitals, and pharmacies defines distribution models, training requirements, and reimbursement touchpoints. Integrating these segmentation lenses enables nuanced product design and market-entry sequencing that align technical feasibility with clinical adoption pathways.

How regional regulatory, reimbursement, and manufacturing landscapes across the Americas, EMEA, and Asia-Pacific influence development priorities and market entry sequencing

Regional dynamics shape prioritization for development, manufacturing, and commercialization of novel delivery systems. In the Americas, innovation clusters in device-enabled biologics and implantable technologies coexist with advanced reimbursement frameworks that can accelerate adoption, but supply chain and tariff considerations necessitate localized manufacturing and regulatory alignment. Europe, Middle East & Africa displays heterogeneity: established regulatory pathways and centralized procurement in some European markets can favor advanced devices and combination products, while emerging markets within the region may prioritize cost-effective, easy-to-administer solutions and decentralized care models. Asia-Pacific presents diverse opportunities driven by large patient populations, expanding clinical trial capacity, and rapid industrial scale-up capabilities, but market entry requires careful navigation of country-specific regulatory nuances and local manufacturing expectations.

These regional contours influence partner selection, clinical development strategies, and commercialization sequencing. For example, companies may prioritize pilot launches in markets with favorable reimbursement policies and strong specialty channel access before expanding into regions where price sensitivity or procurement processes demand alternative value propositions. Similarly, regulatory engagement strategies should reflect regional differences in device and biologic governance, with early dialogue enabling feasibility assessments and pathway optimization. Balancing a global vision with regionalized execution plans is essential to capture adoption momentum while managing operational complexity.

Competitive differentiation driven by integrated technology stacks, strategic collaborations, and a focus on real-world evidence and manufacturing excellence

Competitive dynamics in novel drug delivery systems are characterized by a mix of established pharmaceutical companies, device specialists, and nimble technology innovators. Leading organizations are differentiating through vertically integrated capabilities that span formulation science, device engineering, and manufacturing scale-up, enabling accelerated translation from concept to clinic. Strategic collaborations-ranging from licensing and co-development agreements to equity investments-are common pathways for obtaining complementary competencies, particularly in areas such as nanoparticle engineering, microneedle fabrication, and digital health integration.

Intellectual property remains a central pillar of competitive advantage, as strong patent families around core materials, delivery mechanisms, and device interfaces can create meaningful barriers to entry. However, commercialization success increasingly depends on real-world evidence generation, user-centric design validation, and payer engagement to establish differentiated value. Companies that invest in robust post-market surveillance, adherence analytics, and clinical outcomes studies will be better positioned to defend pricing and expand indications. Manufacturing excellence and regulatory track record are additional differentiators; partners and acquirers favor organizations with demonstrated ability to scale complex biologic formulations, maintain sterility assurance, and navigate combination product submissions efficiently.

Practical and prioritized strategic actions for life sciences leaders to align R&D, supply chain resilience, and commercial evidence generation for sustainable adoption

Industry leaders should adopt a set of prioritized actions to convert technical promise into sustainable commercial outcomes. First, embed delivery strategy early in drug development by co-designing formulations and devices with clinical and regulatory teams, thereby minimizing late-stage redesigns and accelerating approval-readiness. Second, diversify supply chains and qualify alternate materials and vendors to mitigate tariff and geopolitical risks while building redundancy into critical component sourcing. Third, invest in pilot manufacturing and scalable process validation for complex formulations, including liposomal and nanoparticle systems, to reduce time-to-scale when a product advances to pivotal studies.

Additionally, establish strategic partnerships to access complementary capabilities such as microneedle fabrication, implantable device engineering, or digital adherence technologies, and structure agreements to balance risk and upside. Strengthen value demonstration by designing outcomes-based evidence programs that align clinical endpoints with payer requirements and end-user benefits such as reduced hospital visits or improved adherence. Finally, prioritize human factors and training programs to ensure that novel devices and administration routes are intuitive for clinicians and patients, thereby smoothing adoption curves in ambulatory and home-care settings. These integrated actions will improve the likelihood of clinical success and commercial uptake while protecting margin and accelerating patient access.

A reproducible mixed-methods research approach combining rigorous secondary review and expert primary interviews to validate technology readiness and commercial dynamics

This report is grounded in a structured research methodology that blends multi-source secondary analysis with targeted primary inquiry to ensure the findings are robust, actionable, and reproducible. Secondary research included curated reviews of peer-reviewed literature, regulatory guidance documents, patent filings, and technical white papers to map technological trends, regulatory precedents, and materials science advancements. These secondary insights established the foundational taxonomy used to segment routes of administration, enabling technologies, therapeutic applications, product types, and end-user channels.

Primary research involved in-depth interviews with cross-functional stakeholders, including formulation scientists, device engineers, regulatory affairs specialists, clinical investigators, manufacturing leaders, and commercial executives. These conversations validated technical feasibility assessments, surfaced practical barriers to adoption, and clarified procurement and reimbursement dynamics across regions. Quantitative validation checks were performed through triangulation of interview inputs against secondary sources and technology readiness indicators. Finally, internal subject-matter experts synthesized the evidence into scenario analyses and strategic recommendations, with iterative review cycles to address potential bias and ensure clarity for decision-makers.

Synthesis of technological, operational, and commercial imperatives that will determine which delivery innovations translate into scalable clinical and market impact

In conclusion, novel drug delivery systems are transitioning from niche technical demonstrations to core strategic assets that determine therapeutic differentiation and patient outcomes. The convergence of advanced materials, device engineering, and digital health capabilities is expanding what is possible in targeted delivery, sustained release, and minimally invasive administration. At the same time, geopolitical and policy shifts, including tariff changes and regional manufacturing expectations, have made supply chain resilience and localization strategic imperatives that influence both cost structures and regulatory pathways.

To capture the full upside of these trends, organizations must integrate delivery considerations across the product lifecycle, prioritize partnerships to fill capability gaps, and invest in real-world evidence that resonates with payers and clinicians. Those who align scientific ingenuity with pragmatic commercialization planning-ensuring manufacturing readiness, regulatory foresight, and user-centric design-will accelerate adoption and deliver measurable improvements in care. The opportunities are significant, but realizing them requires coordinated action across R&D, operations, and commercial functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Novel Drug Delivery Systems Market, by Product Type

  • 8.1. Depot Injections
    • 8.1.1. Biodegradable
    • 8.1.2. Nonbiodegradable
  • 8.2. DrugEluting Stents
    • 8.2.1. Coronary
    • 8.2.2. Peripheral
  • 8.3. Implantable Pumps
    • 8.3.1. Infusion Pumps
    • 8.3.2. Osmotic Pumps
  • 8.4. Liposomal Formulations
    • 8.4.1. Conventional Liposomes
    • 8.4.2. Stealth Liposomes
  • 8.5. Microneedle Patches
    • 8.5.1. Dissolvable
    • 8.5.2. Solid

9. Novel Drug Delivery Systems Market, by Route Of Administration

  • 9.1. Inhalation
    • 9.1.1. Dry Powder Inhalers
    • 9.1.2. Nebulizers
  • 9.2. Injectable
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Nasal
    • 9.3.1. Drops
    • 9.3.2. Sprays
  • 9.4. Oral
    • 9.4.1. Capsules
    • 9.4.2. Liquids
    • 9.4.3. Tablets
  • 9.5. Transdermal
    • 9.5.1. Gels
    • 9.5.2. Patches

10. Novel Drug Delivery Systems Market, by Technology

  • 10.1. Hydrogels
    • 10.1.1. Natural
    • 10.1.2. Synthetic
  • 10.2. Implants
    • 10.2.1. Biodegradable
    • 10.2.2. Nonbiodegradable
  • 10.3. Microneedles
    • 10.3.1. Coated
    • 10.3.2. Dissolvable
    • 10.3.3. Hollow
    • 10.3.4. Solid
  • 10.4. Nanoparticles
    • 10.4.1. Dendrimers
    • 10.4.2. Liposomes
      • 10.4.2.1. Cationic Liposomes
      • 10.4.2.2. Stealth Liposomes
    • 10.4.3. Polymeric Nanoparticles
    • 10.4.4. Solid Lipid Nanoparticles

11. Novel Drug Delivery Systems Market, by Application

  • 11.1. Cardiovascular
    • 11.1.1. Stents
    • 11.1.2. Transcatheter Devices
  • 11.2. Endocrinology
    • 11.2.1. Diabetes Management
    • 11.2.2. Hormone Replacement
  • 11.3. Infectious Diseases
    • 11.3.1. Antibiotic Delivery
    • 11.3.2. Antiviral Delivery
    • 11.3.3. Vaccine Delivery
  • 11.4. Neurology
    • 11.4.1. CNS Disorders
    • 11.4.2. Peripheral Disorders
  • 11.5. Oncology
    • 11.5.1. Chemotherapy
    • 11.5.2. Immunotherapy
    • 11.5.3. Targeted Therapy
  • 11.6. Ophthalmology
    • 11.6.1. Eye Drops
    • 11.6.2. Ocular Implants

12. Novel Drug Delivery Systems Market, by End User

  • 12.1. Ambulatory Care
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals
  • 12.5. Pharmacies

13. Novel Drug Delivery Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Novel Drug Delivery Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Novel Drug Delivery Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Novel Drug Delivery Systems Market

17. China Novel Drug Delivery Systems Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Baxter International Inc.
  • 18.9. Becton, Dickinson and Company
  • 18.10. Boston Scientific Corporation
  • 18.11. Eli Lilly and Company
  • 18.12. F. Hoffmann-La Roche Ltd.
  • 18.13. Galen Limited
  • 18.14. Gilead Sciences, Inc.
  • 18.15. GlaxoSmithKline plc
  • 18.16. Johnson & Johnson
  • 18.17. Merck & Co., Inc.
  • 18.18. Novartis AG
  • 18.19. Otsuka Pharmaceutical Co., Ltd.
  • 18.20. Pfizer Inc.
  • 18.21. Regeneron Pharmaceuticals, Inc.
  • 18.22. Samyang Holdings Corporation
  • 18.23. Sanofi S.A.
  • 18.24. Takeda Pharmaceutical Company Limited
  • 18.25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OSMOTIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OSMOTIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OSMOTIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCINE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCINE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCINE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CNS DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CNS DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OCULAR IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OCULAR IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OCULAR IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 260. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2032 (USD MILLION)
  • TABLE 261. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 263. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 265. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 267. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2032 (USD MILLION)
  • TABLE 269. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 270. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2032 (USD MILLION)
  • TABLE 271. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 272. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 273. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 275. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 284. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2032 (USD MILLION)
  • TABLE 286. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2032 (USD MILLION)
  • TABLE 288. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 290. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 292. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)

TABLE